26 May 2013
Keywords: tirofiban, cuts, mortality, unstable, angina, patients, merck
Article | 26 March 1997
Merck & Co's glycoprotein IIb/IIIa inhibitor Aggrastat (tirofiban) cutthe risk of death, heart attack and refractory ischemia by over a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 March 1997
24 May 2013
© 2013 thepharmaletter.com